| Genzyme, Icahn Agree To End Proxy Fight Genzyme and Carl Icahn reached an agreement to add two Icahn-backed directors to the biotech company's board, ending a proxy battle. online.wsj.com |
Abiomed, Inc. F1Q11 (Qtr End 06/30/10) Earnings Call Transcript Abiomed, Inc. (ABMD)F1Q11 (Qtr End 06/30/10) Earnings Call TranscriptAugust 4, 2010 8:00 am ETComplete Story » seekingalpha.com |
BioClinica to Demonstrate Global Technology-Enhanced Trial Service Capabilities at Leading Industry Events (Business Wire) NEWTOWN, Pa.----BioClinica™, Inc. , a global provider of clinical trial management services, will attend and speak at several key industry conferences throughout the third and fourth quarters of 2010. us.rd.yahoo.com |
Drug to Prevent Stroke Is Approved The FDA approved Boehringer Ingelheim's blood-thinning drug Pradaxa to prevent strokes in patients with irregular heart rhythms. online.wsj.com |
Glenview Capital Files 13G on Life Technologies Market Folly submits:Larry Robbins' hedge fund Glenview Capital has filed a 13G with the SEC regarding shares of Life Technologies (LIFE). Due to portfolio activity on November 19th, Glenview has disclosed a 5.1% ownership stake LIFE in with 9,450,612 shares. This marks a 17% increase in Robbins' position size since September 30th, as his hedge fund owned 8,077,282 shares at the end of the third quarter.Robbins is obviously fond of this name and recently pitched it at the Invest For Kids Conference in Chicago. You can see notes from his presentation here. In summary, he sees Life Technologies trading at an attractive valuation and thinks the company should buyback shares. In terms of other recent activity out of the hedge fund, we also detailed how Glenview increased its position in Punch Taverns (PCTVY.PK).Complete Story » seekingalpha.com |